Compare HRTG & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | CMPX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.0M | 926.7M |
| IPO Year | 2014 | 2020 |
| Metric | HRTG | CMPX |
|---|---|---|
| Price | $27.14 | $5.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $32.50 | $14.43 |
| AVG Volume (30 Days) | 322.2K | ★ 1.8M |
| Earning Date | 06-12-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.17 | N/A |
| Revenue | ★ $816,985,000.00 | N/A |
| Revenue This Year | $5.45 | N/A |
| Revenue Next Year | $7.27 | $830.89 |
| P/E Ratio | $6.47 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.89 | $1.33 |
| 52 Week High | $31.98 | $6.88 |
| Indicator | HRTG | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 37.33 |
| Support Level | $25.43 | $4.78 |
| Resistance Level | $28.48 | $5.86 |
| Average True Range (ATR) | 1.42 | 0.32 |
| MACD | 0.17 | -0.09 |
| Stochastic Oscillator | 66.38 | 12.21 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance in various states in the United States. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. Company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, South Carolina.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.